SecBot SecBot

NXTC

NextCure, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001661059 Biotech & Drug Discovery
$5.22 +0.24 (+4.92%)
Oct 26 4:00 PM ET · prev $4.98
Market cap
$21.6M
Nano cap
Median target
$20.00
+283% · range $20.00–20.00
Next earnings
Nov 3
in 7 days · EPS est. −$0.90
1 year
−43.6%
from $9.27 · Oct 27
30 days
+2.9%
from $5.08
52-week range
$1.60–14.27
−63% from high · low Jun 30
Avg volume 20D
66.4K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$1.4M
1 buyer · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
13
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 1 bearish · 1 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 3/7 ·Next Earnings date, Nov 3, 2026
Strongest NEUTRAL JP Sailing Capital Ltd and its control person Jianping Huang have filed a new Schedule 13G disclosing a 9.9%…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $1.6M at an average $4.93. 1 insider sold $184.8K. Price is 6% above their cost.

  • InstitutionsBULLISH

    Q2 2026: 3 added (0 new), 0 trimmed or exited.

  • EstimatesRISING

    Current-quarter EPS estimate −$1.630 → −$0.900 over 90 days.

  • TrendRANGE

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
RENAISSANCE TECHNOLOGIES LLCDOUBLED171,202$273.9K
BlackRock, Inc.ADD37,348$59.8K
UBS Group AGADD594$951.00
RENAISSANCE TECHNOLOGIES LLCADD60,534$646.5K
GEODE CAPITAL MANAGEMENT, LLCADD31,092$327.1K
VANGUARD GROUP INCADD91,910$1.3M
UBS Group AGTRIM338$4.8K
BANK OF AMERICA CORP /DE/DOUBLED173$2.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action May 2026
12-month targets · 1 analysts

Price is below the lowest target. Median implies +283%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
May 11, 2026LUCID CAPITAL MARKETS
INITIATE
INITIATEBuy

Insider ledger

Form 4
$1.6M
bought · 1 insider
$184.8K
sold · 1 insider
+5.9%
vs their $4.93 cost
DateInsiderTypeValue
Aug 10, 2026
Simcere Zaiming, Inc.
SELL$184.8K
Jul 31, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$38.4K
Jul 31, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$124.5K
Jul 31, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$16.4K
Jul 30, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$100.0K
Jul 30, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$248.6K
Jul 30, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$385.8K
Jul 30, 2026
ADAR1 Capital Management, LLC
10%+ Owner
BUY$490.0K

Earnings setup

Estimates
Nov 3
reports in 7 days
−$0.90
EPS estimate, this quarter
+45%
estimate change, 90 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.90-$0.90–-$0.90+50.8%$0.00
Next Q-$0.79-$0.79–-$0.79+58.2%$0.00
Current FY-$6.34-$6.34–-$6.34+15.0%$0.00
Next FY-$5.89-$10.41–-$1.38+16.6%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Jul 16, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
JP Sailing Capital Ltd and its control person Jianping Huang have filed a new Schedule 13G disclosing a 9.9% passive…
SC 13G — Impact 4/10
Sep 25, 2026 SEC
NextCure filed a Section 205 petition in Delaware Chancery Court seeking validation of its July 2025 reverse stock…
425 — Impact 5/10
Sep 25, 2026 SEC
NextCure filed a Section 205 petition in the Delaware Court of Chancery seeking judicial validation of its July 2025…
8-K — Impact 5/10
Aug 26, 2026 Event
HSR Early Termination: NextCure, Inc.; Avere Therapeutics, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving NextCure
Aug 10, 2026 Insider
Simcere Zaiming, Inc. sold 30,000 shares
$6.16 ($184.8K)
Aug 6, 2026 Earnings
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
BELTSVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage b
Jul 31, 2026 Insider
ADAR1 Capital Management, LLC bought 8,003 shares
10%+ Owner @ $4.80 ($38.4K)
Jul 31, 2026 Insider
ADAR1 Capital Management, LLC bought 25,000 shares
10%+ Owner @ $4.98 ($124.5K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 3, 2026
Earnings date
NXTC Q3 2026 Earnings Scheduled — 2026-11-03
Recent
Aug 26, 2026
Enforcement
HSR Early Termination: NextCure, Inc.; Avere Therapeutics, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving NextCure, Inc.; Avere Therapeutics, Inc..
Aug 13, 2026
Clinical Trial
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
Phase 2 · TERMINATED
Aug 6, 2026
Earnings
NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results
BELTSVILLE, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to…
Aug 5, 2026
Earnings date
NXTC Q2 2026 Earnings Scheduled — 2026-08-05
Jul 16, 2026
Trading halt
Halt Resumed: NXTC — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-07-16T14:36:39.000Z | Resumed 2026-07-16T14:41:39.000Z

SecBot reports

13 filings · 4 press releases · 3 bullish · 2 bearish · 8 neutral
All NXTC filing & press-release reports (17)